




Solaxa

SCA27B Clinical Trial Update

Mary Hogan

Head of Scientific Affairs & Patient
Access



SLX-100 SCA27B 301 Study

- Pivotal-powered study funded in part by a \$7.3M grant awarded to Dr. Susan Perlman, MD, at UCLA by the Congressionally Directed Medical Research Program
 - Rare Diseases – Hereditary Ataxia
 - Clinical response of SLX-100 in SCA27B patients
 - **Solaxa** – regulatory sponsor
 - Status:
 - AUG 1, 2025 - Money released to **UCLA** as the prime site
 - UCLA will subcontract other sites and equip
 - UCLA will be the first site to recruit patients
 - Timeline to begin patient recruitment is dependent on:
 - FDA – final protocol submitted & awaiting feedback
 - IRB – final protocol is under review & awaiting feedback
 - Solaxa securing additional funding to cover non-grant related expenses
 - Future Plans: expand trial beyond SCA27B to other ataxias
-